Raloxifene Upregulated Mesangial Cell MMP-2 Activity via ER-β Through Transcriptional Regulation

Cell Biochemistry and Biophysics

Volumn 67, Issue 2, 2013, Pages 607-613

  Fang, Ming ^a   Wu, Xin Chi ^a   Huang, Wenlong ^a  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

AP 2; Diabetic nephropathy; ER ; MMP 2; Raloxifene

Indexed keywords

MUS;

ESTROGEN RECEPTOR BETA; GELATINASE A; PROTEIN KINASE INHIBITOR; RALOXIFENE; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSCRIPTION FACTOR AP 2;

ANIMAL; ARTICLE; BLOOD; BODY WEIGHT; DIABETES MELLITUS; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; GLUCOSE BLOOD LEVEL; MESANGIUM CELL; METABOLISM; MOUSE; PATHOLOGY; SECRETION (PROCESS); UPREGULATION;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS; ESTROGEN RECEPTOR BETA; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; MATRIX METALLOPROTEINASE 2; MESANGIAL CELLS; MICE; PROTEIN KINASE INHIBITORS; RALOXIFENE; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TRANSCRIPTION FACTOR AP-2; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 84886585941     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-013-9548-1     Document Type: Article

References (41)

1. Hansdóttir, H. (2008). Raloxifene for older women: A review of the literature. Clinical Interventions in Aging, 3, 45-50.
2. Ko, S. S., & Jordan, V. C. (2011). Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene. Expert Opinion on Pharmacotherapy, 12, 657-674.
3. Ogita, H., Node, K., Asanuma, H., Sanada, S., Liao, Y., Takashima, S., et al. (2002). Amelioration of ischemia- and reperfusion-induced myocardial injury by the selective estrogen receptor modulator, raloxifene, in the canine heart. Journal of Cardiology, 39, 55-56.
4. Ogita, H., Node, K., Asanuma, H., Sanada, S., Kim, J., Takashima, S., et al. (2004). Raloxifene improves coronary perfusion, cardiac contractility, and myocardial metabolism in the ischemic heart: Role of phosphatidylinositol 3-kinase/Akt pathway. Journal of Cardiovascular Pharmacology, 43, 821-829.
5. Chin, M., Isono, M., Isshiki, K., Araki, S., Sugimoto, T., Guo, B., et al. (2005). Estrogen and raloxifene, a selective estrogen receptor modulator, ameliorate renal damage in db/db mice. American Journal of Pathology, 166, 1629-1636.
6. Fioretto, P., Steffes, M. W., Sutherland, D. E., Goetz, F. C., & Mauer, M. (1998). Reversal of lesions of diabetic nephropathy after pancreas transplantation. New England Journal of Medicine, 339, 69-75.
7. Davies, M., Martin, J., Thomas, G. J., & Lovett, D. H. (1992). Proteinases and glomerular matrix turnover. Kidney International, 41, 671-678.
8. McLennan, S. V., Death, A. K., Fisher, E. J., Williams, P. F., Yue, D. K., & Turtle, J. R. (1999). The role of the mesangial cell and its matrix in the pathogenesis of diabetic nephropathy. Cellular and Molecular Biology, 45, 123-135.
9. Nguyen, D., Ping, F., Mu, W., Hill, P., Atkins, R. C., & Chadban, S. J. (2006). Macrophage accumulation in human progressive diabetic nephropathy. Nephrology (Carlton, Vic.), 11, 226-231.
10. Reunanen, N., Westermarck, J., Hakkinen, L., Holmstrom, T. H., Elo, I., Eriksson, J. E., et al. (1998). Enhancement of fibroblast collagenase (matrix metalloproteinase-1) gene expression by ceramide is mediated by extracellular signal-regulated and stress-activated protein kinase pathways. The Journal of Biological Chemistry, 273, 5137-5145.
11. Lai, W. C., Zhou, M., Shankavaram, U., Peng, G., & Wahl, L. M. (2003). Differential regulation of lipopolysaccharide-induced monocyte matrix metalloproteinase (MMP)-1 and MMP-9 by p38 and extracellular signal-regulated kinase 1/2 mitogen-activated protein kinases. Journal of Immunology, 170, 6244-6249.
12. Wahl, S. M., Wahl, L. M., McCarthy, J. B., Chedid, L., & Mergenhagen, S. E. (1979). Macrophage activation by mycobacterial water soluble compounds and synthetic muramyl dipeptide. Journal of Immunology, 122, 2226-2231.
13. van Wart, H. E., & Birkedal-Hansen, H. (1990). The cysteine switch: A principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proceedings of the National Academy of Sciences of the United States of America, 87, 5578-5582.
14. Miltenburg, A. M., Lacraz, S., Welgus, H. G., & Dayer, J. M. (1995). Immobilized anti-CD3 antibody activates T cell clones to induce the production of interstitial collagenase, but not tissue inhibitor of metalloproteinases, in monocytic THP-1 cells and dermal fibroblasts. Journal of Immunological, 154, 2655-2667.
15. Lacraz, S., Isler, P., Vey, E., Welgus, H. G., & Dayer, J. M. (1994). Direct contact between T lymphocytes and monocytes is a major pathway for induction of metalloproteinase expression. The Journal of Biological Chemistry, 269, 22027-22033.
16. Duong van Huyen, J. P., Viltard, M., Nehiri, T., Freund, N., Bélair, M. F., Martinerie, C., et al. (2007). Expression of matrix metalloproteinases MMP-2 and MMP-9 is altered during nephrogenesis in fetuses from diabetic mice. Laboratory Investigation, 87, 680-689.
17. Lenz, O., Elliot, S. J., & Stetler-Stevenson, W. G. (2000). Matrix metalloproteinases in renal development and disease. Journal of the American Society of Nephrology, 11, 574-581.
18. Guccione, M., Silbiger, S., Lei, J., & Neugarten, J. (2002). Estradiol upregulates mesangial cell MMP-2 activity via the transcription factor AP-2. American Journal of Physiology. Renal Physiology, 282, F164-F169.
19. Akis, N., & Madio, M. P. (2004). Isolation, culture, and characterization of endothelial cells from mouse glomeruli. Kidney International, 65, 2223-2227.
20. Han, S. Y., Jee, Y. H., Han, K. H., Kang, Y. S., Kim, H. K., Han, J. Y., et al. (2006). An imbalance between matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 contributes to the development of early diabetic nephropathy. Nephrology, Dialysis, Transplantation, 21, 2406-2416.
21. Neugarten, J., Acharya, A., & Silbiger, S. R. (2000). The effect of gender on the progression of non-diabetic renal disease: A metaanalysis. Journal of the American Society of Nephrology, 11, 319-329.
22. Silbiger, S., & Neugarten, J. (1995). The impact of gender on the progression of chronic renal disease. American Journal of Kidney Diseases, 25, 515-533.
23. Breyer, J. A., Bain, R. P., Evans, J. K., Nahman, N. S, Jr, Lewis, E. J., Cooper, M., et al. (1996). Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. The Collaborative Study Group. Kidney International, 50, 1651-1658.
24. Cherney, D. Z., Sochett, E. B., & Miller, J. A. (2005). Gender differences in renal responses to hyperglycemia and angiotensin-converting enzyme inhibition in diabetes. Kidney International, 68, 1722-1728.
25. Mankhey, R. W., Bhatti, F., & Maric, C. (2005). 17beta-Estradiol replacement improves renal function and pathology associated with diabetic nephropathy. American Journal of Physiology. Renal Physiology, 288, F399-F405.
26. Wells, C. C., Riazi, S., Mankhey, R. W., Bhatti, F., Ecelbrager, C., & Maric, C. (2005). Diabetic nephropathy is associated with decreased circulating estradiol levels and imbalance in the expression of renal estrogen receptors. Gender Medicine, 2, 227-237.
27. He, M., Zhang, L., Shao, Y., Wang, X., Huang, Y., Yao, T., et al. (2009). Inhibition of renin/prorenin receptor attenuated mesangial cell proliferation and reduced associated fibrotic factor release. European Journal of Pharmacology, 606, 155-161.
28. Wang, S., & Hirschberg, R. (2003). BMP7 antagonizes TGF-beta -dependent fibrogenesis in mesangial cells. American Journal of Physiology. Renal Physiology, 284, F1006-F1013.
29. Sun, S., Wang, Y., Li, Q., Tian, Y., Liu, M., & Yu, Y. (2006). Effects of benazepril on renal function and kidney expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in diabetic mice. Chinese Medical Journal, 119, 814-821.
30. Mankhey, R., Wells, C. C., Bhatti, F., & Maric, C. (2006). 17-beta estradiol supplementation reduces tubulointerstitial fibrosis by increasing MMP activity in the diabetic kidney. American Journal of Physiology. Regulatory Integrative and Comparative Physiology, 292, R769-R777.
31. McLennan, S. V., Kelly, D. J., Cox, A. J., Cao, Z., Lyons, J. G., Yue, D. K., et al. (2002). Decreased matrix degradation in diabetic nephropathy: Effects of ACE inhibition on the expression and activities of matrix metalloproteinases. Diabetologia, 45, 268-275.
32. Sato, H., Takino, T., Okada, Y., Cao, J., Shinagawa, A., Yamamoto, E., et al. (1994). A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature, 370, 61-65.
33. Ohuchi, E., Imai, K., Fujii, Y., Sato, H., Seiki, M., & Okada, Y. (1997). Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. The Journal of Biological Chemistry, 272, 2446-2451.
34. McLennan, S. V., Martell, S. Y., & Yue, D. K. (2000). High glucose concentration inhibits the expression of membrane type metalloproteinase by mesangial cells: Possible role in mesangium accumulation. Diabetologia, 43, 642-648.
35. Strongin, A. Y., Collier, I., Bannikov, G., Marmer, B. L., Grant, G. A., & Goldberg, G. I. (1995). Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. The Journal of Biological Chemistry, 270, 5331-5338.
36. Wołczynski, S., Surazyński, A., Swiatecka, J., & Pałka, J. (2001). Estrogenic and antiestrogenic effects of raloxifene on collagen metabolism in breast cancer MCF-7 cells. Gynecological Endocrinology, 15, 225-233.
37. Mertens, P. R., Harendza, S., Pollock, A. S., & Lovett, D. H. (1997). Glomerular mesangial cell-specific transactivation of matrix metalloproteinase 2 transcription is mediated by YB-1. The Journal of Biological Chemistry, 272, 22905-22912.
38. Grumont, R. J., Rasko, J. E. J., Strasser, A., & Gerondakis, S. (1996). Activation of the mitogen-activated protein kinase pathway induces transcription of the PAC-1 phosphatase gene. Molecular and Cellular Biology, 16, 2913-2921.
39. Milanini, J., Vinals, F., Pouyssegur, J., & Pages, G. (1998). p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts. The Journal of Biological Chemistry, 273, 18165-18172.
40. Neuharten, J., Acharya, A., Lei, J., & Silbiger, S. (2000). Selective estrogen receptor modulators suppress mesangial cell collagen synthesis. American Journal of Physiology. Renal Physiology, 279, F309-F318.
41. Cohen, M. P., Clements, R. S., Hud, E., Cohen, J. A., & Ziyadeh, F. N. (1996). Evolution of renal function abnormalities in the db/db mouse that parallels the development of human diabetic nephropathy. Experimental Nephrology, 4, 166-171.